放射性核素131I在甲亢治疗中的安全性与有效性分析(1)
摘 要：目的 分析放射性核素131I在甲亢治疗中的安全性与有效性。方法 回顾性分析2015年8月～2017年8月本院收治的64例甲亢患者，按照随机数字表法将其分为实验组和对照组，各32例，对照组患者给予丙硫氧嘧啶片治疗，实验组患者给予丙硫氧嘧啶片+131I治疗，观察两组患者的治疗总有效率、不良反应发生率、FT3、FT4及TSH变化水平。结果 实验组临床总有效率87.50%高于对照组的62.50%，差异有统计学意义(P<0.05)；实验组不良反应发生率3.75%低于对照组31.25%，差异有统计学意义(P<0.05)；治疗后，实验组患者FT3、FT4、TSH水平均优于对照组，差异有统计学意义(P<0.05)。结论 放射性核素131I在甲亢治疗中可有效提高治疗效果，改善患者FT3、FT4及TSH水平，不良反应少。
关键词：FT3；FT4；131I；甲亢；丙硫氧嘧啶
中图分类号：R581.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.15.038
, 百拇医药
文章编号：1006-1959(2018)15-0120-03
Safety and Efficacy Analysis of Radionuclide 131I in the Treatment of Hyperthyroidism
SUN Qing-lin
(Department of Nuclear Medicine，the First People's Hospital of Yancheng，Yancheng 224005，Jiangsu，China)
Abstract：Objective To analyze the safety and efficacy of radionuclide 131I in the treatment of hyperthyroidism.Methods A retrospective analysis of 64 patients with hyperthyroidism admitted to our hospital from August 2015 to August 2017 was divided into experimental group and control group according to the random number table method，32 cases in each group.Patients in the control group were treated with propylthiouracil tablets.Patients in the experimental group were treated with propylthiouracil tablets+131I.The total effective rate，adverse reaction rate，FT3，FT4and TSH levels were observed in the two groups.Results The total effective rate of the experimental group was 87.50% higher than that of the control group 62.50%，the difference was statistically significant(P<0.05). The incidence of adverse reactions in the experimental group was 3.75% lower than that in the control group 31.25%，the difference was statistically significant(P<0.05)；After treatment，the FT3，FT4，and TSH levels in the experimental group were better than those in the control group，and the difference was statistically significant(P<0.05).Conclusion Radionuclide 131I can effectively improve the therapeutic effect in the treatment of hyperthyroidism，improve the levels of FT3，FT4 and TSH in patients with less adverse reactions.
, 百拇医药
Key words：FT3；FT4；131I；Hyperthyroidism；Propylthiouracil
甲亢(hyperthyroidism)是由于甲狀腺合成释放过多的甲状腺激素，造成机体代谢亢进和交感神经兴奋，引起心悸、出汗、进食、消瘦等症状，甲亢主要是由弥漫性毒性甲状腺肿、亚急性甲状腺炎、无痛性甲状腺炎、产后甲状腺炎和桥本甲亢、左甲状腺素钠或碘过量所致甲亢、妊娠呕吐性暂时性甲亢、垂体TSH瘤甲亢等原因造成[1]。目前临床上多采用药物治疗甲亢，如硫氧嘧啶、甲巯咪唑等，但需患者长期服用药物，疾病复发率较高[2]，致使患者精神压力较大。基于此，选择一种有效、安全的治疗方法极其重要。本次实验旨在研究放射性核素131I在甲亢治疗中的安全性与有效性，现汇报如下。
1 资料与方法
1.1一般资料 选择江苏省盐城市第一人民医院2015年8月～2017年8月收治的64例甲亢患者，按照随机数字表法分为实验组和对照组，各32例。实验组中男10例，女22例，年龄49～61岁，平均年龄(54.50±5.50)岁，病程0.2～2年，平均病程(1.10±0.70)年，体质量指数24～28 kg/m2，平均体质量指数(25.80±1.50)kg/m2，初诊患者24例，复发患者8例。对照组中男10例，女21例，年龄50～62岁，平均年龄(55.80±5.50)岁，病程0.3～2.2年，平均病程(1.25±0.65)年，体质量指数23～27 kg/m2，平均体质量指数(24.90±1.20)kg/m2，初诊患者23例，复发患者9例，两组患者性别、年龄、病程等基本资料比较，差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(孙清林)
关键词：FT3；FT4；131I；甲亢；丙硫氧嘧啶
中图分类号：R581.1 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.15.038
, 百拇医药
文章编号：1006-1959(2018)15-0120-03
Safety and Efficacy Analysis of Radionuclide 131I in the Treatment of Hyperthyroidism
SUN Qing-lin
(Department of Nuclear Medicine，the First People's Hospital of Yancheng，Yancheng 224005，Jiangsu，China)
Abstract：Objective To analyze the safety and efficacy of radionuclide 131I in the treatment of hyperthyroidism.Methods A retrospective analysis of 64 patients with hyperthyroidism admitted to our hospital from August 2015 to August 2017 was divided into experimental group and control group according to the random number table method，32 cases in each group.Patients in the control group were treated with propylthiouracil tablets.Patients in the experimental group were treated with propylthiouracil tablets+131I.The total effective rate，adverse reaction rate，FT3，FT4and TSH levels were observed in the two groups.Results The total effective rate of the experimental group was 87.50% higher than that of the control group 62.50%，the difference was statistically significant(P<0.05). The incidence of adverse reactions in the experimental group was 3.75% lower than that in the control group 31.25%，the difference was statistically significant(P<0.05)；After treatment，the FT3，FT4，and TSH levels in the experimental group were better than those in the control group，and the difference was statistically significant(P<0.05).Conclusion Radionuclide 131I can effectively improve the therapeutic effect in the treatment of hyperthyroidism，improve the levels of FT3，FT4 and TSH in patients with less adverse reactions.
, 百拇医药
Key words：FT3；FT4；131I；Hyperthyroidism；Propylthiouracil
甲亢(hyperthyroidism)是由于甲狀腺合成释放过多的甲状腺激素，造成机体代谢亢进和交感神经兴奋，引起心悸、出汗、进食、消瘦等症状，甲亢主要是由弥漫性毒性甲状腺肿、亚急性甲状腺炎、无痛性甲状腺炎、产后甲状腺炎和桥本甲亢、左甲状腺素钠或碘过量所致甲亢、妊娠呕吐性暂时性甲亢、垂体TSH瘤甲亢等原因造成[1]。目前临床上多采用药物治疗甲亢，如硫氧嘧啶、甲巯咪唑等，但需患者长期服用药物，疾病复发率较高[2]，致使患者精神压力较大。基于此，选择一种有效、安全的治疗方法极其重要。本次实验旨在研究放射性核素131I在甲亢治疗中的安全性与有效性，现汇报如下。
1 资料与方法
1.1一般资料 选择江苏省盐城市第一人民医院2015年8月～2017年8月收治的64例甲亢患者，按照随机数字表法分为实验组和对照组，各32例。实验组中男10例，女22例，年龄49～61岁，平均年龄(54.50±5.50)岁，病程0.2～2年，平均病程(1.10±0.70)年，体质量指数24～28 kg/m2，平均体质量指数(25.80±1.50)kg/m2，初诊患者24例，复发患者8例。对照组中男10例，女21例，年龄50～62岁，平均年龄(55.80±5.50)岁，病程0.3～2.2年，平均病程(1.25±0.65)年，体质量指数23～27 kg/m2，平均体质量指数(24.90±1.20)kg/m2，初诊患者23例，复发患者9例，两组患者性别、年龄、病程等基本资料比较，差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(孙清林)